Entelexo Biotherapeutics
Private Company
Funding information not available
Overview
Entelexo Biotherapeutics is a private, pre-clinical stage biotech leveraging engineered exosomes to treat complex autoimmune diseases. Its core innovation is a rational engineering platform that designs exosomes to deliver targeted messages to multiple diseased cell types at once, moving beyond single-pathway blockade. The company has built an initial pipeline, de-risked candidates in human cell assays, and is progressing toward IND-enabling studies, having secured pre-seed funding and notable accelerator support.
Technology Platform
Proprietary rational engineering platform for designing exosomes that can deliver targeted therapeutic messages to multiple specific cell types simultaneously.
Opportunities
Risk Factors
Competitive Landscape
Entelexo competes in the emerging exosome/exracellular vesicle therapeutics space, alongside other biotechs like Codiak BioSciences, Evox Therapeutics, and Capricor Therapeutics. It also competes broadly with developers of next-generation immunomodulators (e.g., cell therapies, multi-specific antibodies) for complex autoimmune diseases.